Annals of Oncology Advance Access originally published online on January 23, 2009
Annals of Oncology 2009 20(4):789-790; doi:10.1093/annonc/mdn793
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
letters to the editor |
CD5 expression in de novo diffuse large B-cell lymphomas
| The first 10% of the full text of this article appears below. |
Ennishi et al. [1] recently described de novo CD5-positive diffuse large B-cell lymphomas (CD5+ DLBCLs), which are now recognized in the new 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid tumors as an immunohistochemical subgroup of DLBCL not otherwise specified. We looked for immunohistochemical
Institute of Pathology, University Hospital of Basel, Switzerland
* (E-mail: philip.went@mac.com)